We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Almost a year after admitting it manipulated safety data for its anemia drug roxadustat, Fibrogen has disclosed that the Securities and Exchange Commission (SEC) is investigating its actions. Read More
Eli Lilly’s Olumiant (baricitinib), a powerful anti-inflammatory used to treat rheumatoid arthritis, has once again proven its mettle against COVID-19. Read More
Nevada’s action marks a growing trend among states to try to rein in the rising costs of prescription drugs — especially as the latest federal attempt at allowing Medicare to negotiate the price of some medications is stalled in the Senate. Read More
The nonprofit generic drugmaker Civica said that it’s going to manufacture three different insulin biosimilars that, if approved, will be distributed at prices that are “significantly lower” than the cost of insulin products that are currently available on the market. Read More
AstraZeneca’s and Sanofi’s investigational long-acting antibody aimed at infants with respiratory syncytial virus (RSV) had positive results in its phase 3 trial, making it the first potential immunization to show protection against RSV in the general infant population in a phase 3 trial, the companies said. Read More
Gantenerumab, another anti-amyloid antibody, is entering the race to find an effective therapy for Alzheimer’s disease (AD), with an ambitious four-year study in presymptomatic, amyloid-positive subjects. Read More